Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
SW Wang, C Gao, YM Zheng, L Yi, JC Lu, XY Huang… - Molecular cancer, 2022 - Springer
Clustered regularly interspaced short palindromic repeats (CRISPR) system provides
adaptive immunity against plasmids and phages in prokaryotes. This system inspires the …
adaptive immunity against plasmids and phages in prokaryotes. This system inspires the …
Co-opting signalling molecules enables logic-gated control of CAR T cells
AM Tousley, MC Rotiroti, L Labanieh, LW Rysavy… - Nature, 2023 - nature.com
Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Navigating CAR-T cells through the solid-tumour microenvironment
AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma
The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Y Gong, RGJ Klein Wolterink, J Wang, GMJ Bos… - Journal of hematology & …, 2021 - Springer
Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are
considered as specialized immune cells that can be genetically modified to obtain capable …
considered as specialized immune cells that can be genetically modified to obtain capable …
CAR T cell therapy for solid tumors: bright future or dark reality?
J Wagner, E Wickman, C DeRenzo, S Gottschalk - Molecular therapy, 2020 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
CAR T cell therapies for patients with multiple myeloma
L Mikkilineni, JN Kochenderfer - Nature reviews Clinical oncology, 2021 - nature.com
Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …
remains largely incurable, indicating a need for new treatment approaches. Chimeric …
Chimeric antigen receptor therapy
CH June, M Sadelain - New England Journal of Medicine, 2018 - Mass Medical Soc
Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic
immunity, with a focus on producing durable remissions in patients with treatment-refractory …
immunity, with a focus on producing durable remissions in patients with treatment-refractory …